Literature DB >> 11934658

Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent.

N H Bjarnason1, P Alexandersen, C Christiansen.   

Abstract

In this study we examine the influence of number of years since menopause on spontaneous bone loss and response to hormone replacement therapy (HRT) in 274 women (56.1 +/- 4.2 years) completing two placebo-controlled HRT studies of 2 or 3 year duration. Both cross sectionally and longitudinally, bone loss in untreated women was greatest closest to menopause and declined thereafter (r = 0.34, p < 0.01 for lumbar spine bone loss and r = 0.25, p < 0.05 for femoral neck bone loss when correlated with number of years since menopause), such that the loss was eliminated in the femoral neck and bone mass increased in the spine in women >10 years after menopause. In contrast, bone turnover was consistently elevated throughout postmenopause, both cross-sectionally and longitudinally. The association with number of years since menopause was counteracted by both 1 and 2 mg estradiol combined with gestodene, piperazine, estrone sulfate in combination with norethisterone, and a combination of 2 mg estradiol and 1 mg norethisterone acetate. In addition, the response to various HRT regimens was independent of baseline bone mass. Whereas bone loss was significantly related to number of years since menopause, all HRT regimens applied arrested bone loss in healthy postmenopausal women, regardless of number of years since menopause.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934658     DOI: 10.1016/s8756-3282(02)00678-6

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.

Authors:  Sonia Baldi; Angelamaria Becorpi
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women.

Authors:  J Wu; L Xu; Y Lv; L Dong; Q Zheng; L Li
Journal:  Osteoporos Int       Date:  2017-03-23       Impact factor: 4.507

Review 3.  Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms.

Authors:  David F Archer
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

4.  Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.

Authors:  Maurizio Rossini; Stefano Lello; Ignazio Sblendorio; Ombretta Viapiana; Elena Fracassi; Silvano Adami; Davide Gatti
Journal:  Drug Des Devel Ther       Date:  2013-07-22       Impact factor: 4.162

5.  Alendronate sodium in the management of osteoporosis.

Authors:  P J J Prinsloo; D J Hosking
Journal:  Ther Clin Risk Manag       Date:  2006-09       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.